Merck (MRK) Net Margin (2009 - 2026)
Merck (MRK) reported Net Margin of 25.84% for Q1 2026, down 5859.0% year-over-year from 0.45% in Q1 2025, and down 243.09% on a QoQ basis from 18.06% in Q4 2025.
Merck (MRK) has 17 years of Net Margin data on file, last reported at 25.84% in Q1 2026.
- Quarterly Net Margin fell 5859.0% year-over-year to 25.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.64% (down 1366.0% YoY) and the FY2025 annual result came in at 28.09%, up 139.0% from the prior year.
- Net Margin fell to 25.84% in Q1 2026 per MRK's latest filing, from 18.06% in the prior quarter.
- Across five years, Net Margin topped out at 33.89% in Q2 2024 and bottomed at 39.49% in Q2 2023.
- The 4-year median for Net Margin is 23.96% (2024), against an average of 14.99%.
- The widest annual swing landed in 2024, when Net Margin soared 7338 bps; it then sank 5859 bps in 2026.
- Tracing MRK's Net Margin over 4 years: stood at 8.38% in 2023, then surged by 386 bps to 23.96% in 2024, then fell by 25 bps to 18.06% in 2025, then sank by 243 bps to 25.84% in 2026.
- Per Business Quant, the three latest MRK Net Margin figures stand at 25.84% (Q1 2026), 18.06% (Q4 2025), and 33.5% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 23.32% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.84% |
| Dec 31, 2025 | 18.06% |
| Sep 30, 2025 | 33.50% |
| Jun 30, 2025 | 28.01% |
| Mar 31, 2025 | 32.75% |
| Dec 31, 2024 | 23.96% |
| Sep 30, 2024 | 18.98% |
| Jun 30, 2024 | 33.89% |
| Mar 31, 2024 | 30.22% |
| Dec 31, 2023 | -8.38% |
| Sep 30, 2023 | 29.76% |
| Jun 30, 2023 | -39.49% |
| Mar 31, 2023 | 19.50% |
| Dec 31, 2021 | -0.46% |
| Jun 30, 2021 | 2.91% |
| Mar 31, 2021 | 4.11% |
| Dec 31, 2020 | 4.78% |
| Sep 30, 2020 | 5.65% |
| Jun 30, 2020 | 7.07% |
| Mar 31, 2020 | 26.70% |
| Dec 31, 2019 | -43.58% |
| Sep 30, 2019 | 15.38% |
| Jun 30, 2019 | 22.48% |
| Mar 31, 2019 | 26.46% |
| Dec 31, 2018 | 16.17% |
| Sep 30, 2018 | 18.14% |
| Jun 30, 2018 | 16.40% |
| Mar 31, 2018 | 7.38% |
| Dec 31, 2017 | -9.95% |
| Sep 30, 2017 | -0.49% |
| Jun 30, 2017 | 19.65% |
| Mar 31, 2017 | 16.49% |
| Dec 31, 2016 | -5.80% |
| Sep 30, 2016 | 20.77% |
| Jun 30, 2016 | 12.28% |
| Mar 31, 2016 | 12.13% |
| Dec 31, 2015 | 9.61% |
| Sep 30, 2015 | 18.18% |
| Jun 30, 2015 | 7.03% |
| Mar 31, 2015 | 10.16% |
| Dec 31, 2014 | 69.90% |
| Sep 30, 2014 | 7.98% |
| Jun 30, 2014 | 18.59% |
| Mar 31, 2014 | 16.86% |
| Dec 31, 2013 | 7.20% |
| Sep 30, 2013 | 10.42% |
| Jun 30, 2013 | 8.49% |
| Mar 31, 2013 | 15.14% |
| Dec 31, 2012 | -12.73% |
| Sep 30, 2012 | 15.35% |
| Jun 30, 2012 | 14.78% |
| Mar 31, 2012 | 15.06% |
| Dec 31, 2011 | -7.18% |
| Sep 30, 2011 | 14.34% |
| Jun 30, 2011 | 16.90% |
| Mar 31, 2011 | -11.95% |
| Dec 31, 2010 | -33.76% |
| Sep 30, 2010 | -18.73% |
| Jun 30, 2010 | -14.58% |
| Mar 31, 2010 | -18.44% |
| Dec 31, 2009 | 109.19% |
| Sep 30, 2009 | 7.88% |
| Jun 30, 2009 | 10.73% |
| Mar 31, 2009 | 14.91% |